Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.
Individuals produce unique sets of antibodies in response to HIV infection. That diversity — and the ability of the human immunodeficiency virus to rapidly change its protein coat to avoid detection — has stymied efforts to develop an anti-HIV vaccine.
